A systematic review on UROMUNE (MV140) has been published. All relevant clinical studies published have been considered to globally assess the impact of this vaccine in the treatment of recurrent urinary tract infections.
UROMUNE (MV140) is a sublingual bacterial vaccine developed by INMUNOTEK designed to prevent recurrent urinary tract infections (rUTIs). In the vast majority of cases, rUTIs affect women in form of recurrent cystitis. As UTIs are caused by bacteria, the conventional treatment is based on antibiotics.
The review, published in Can Urol Assoc J, has assessed the clinical efficacy of UROMUNE (MV140) in the prevention of this type of pathology from published clinical data. The authors’ s conclusion is that this vaccine can be an alternative to antibiotics to avoid the infection recurrence.
Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future
J. Curtis Nickel, MD, FRCSC,corresponding author(1), Paula Saz-Leal, PhD,(2) and R. Christopher Doiron, MD(1)
1) Department of Urology, Queen’s University, Kingston, ON, Canada 2) Inmunotek S.L., Alcalá de Henares, Madrid, Spain